EB-1089

EB-1089_structure.png Chemical structure of EB-1089

EB-1089, also known as Seocalcitol, is a synthetic analogue of calcitriol, the hormonally active form of vitamin D3. It has been studied for its potential use in the treatment of various types of cancer, particularly breast cancer and prostate cancer.

Mechanism of Action

EB-1089 functions by binding to the vitamin D receptor (VDR), which is a type of nuclear receptor that regulates the expression of genes involved in cell proliferation, differentiation, and apoptosis. By modulating these pathways, EB-1089 can inhibit the growth of cancer cells and induce their differentiation or death.

Pharmacokinetics

EB-1089 is designed to have a higher potency and a longer half-life than calcitriol, which allows for more effective dosing regimens in clinical settings. It is metabolized in the liver and excreted primarily through the bile.

Clinical Studies

Several clinical trials have been conducted to evaluate the efficacy and safety of EB-1089 in cancer treatment. Early-phase trials have shown promising results in reducing tumor size and improving survival rates in patients with advanced cancers. However, further studies are needed to fully establish its therapeutic potential and optimal dosing strategies.

Side Effects

As with other vitamin D analogues, the primary side effect of EB-1089 is hypercalcemia, which is an elevated level of calcium in the blood. This can lead to symptoms such as nausea, vomiting, and confusion. Careful monitoring of calcium levels is necessary during treatment.

Research and Development

Research on EB-1089 is ongoing, with studies focusing on its use in combination with other anticancer agents and its potential role in overcoming resistance to conventional therapies. The development of EB-1089 is part of a broader effort to harness the anticancer properties of vitamin D analogues.

Also see

• Calcitriol
• Vitamin D receptor
• Breast cancer treatment
• Prostate cancer treatment